Second treated eyes with nAMD functionally more important than first eyes

A real-world study of the characteristics of second treated eyes in patients with neovascular age-related macular degeneration given ranibizumab in the UK National Health Service has shown that these eyes start off with better baseline visual acuity than first treated eyes and, despite a poor response to therapy, maintain this advantage.